loading page

Can HLA type I and II alleles presence be associated with the clinical spectrum of CHIKV infection?
  • +11
  • Juan C. Rueda,
  • Ana M. Santos,
  • Jose-Ignacio Angarita,
  • Eugenia-Lucia Saldarriaga,
  • Ingris Peláez-Ballestas,
  • Alejandro Silva Espinosa,
  • Ignacio Briceño-Balcázar,
  • Sofia Arias-Correal,
  • José Arias Correal,
  • Catalina Villota-Erazo,
  • Viviana Reyes,
  • Santiago Bernal-Macías,
  • Mario H. Cardiel,
  • John Londono
Juan C. Rueda
Student from the Biosciences Programme Faculty of Medicine and Engineering Universidad de La Sabana Chía Colombia

Corresponding Author:[email protected]

Author Profile
Ana M. Santos
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Jose-Ignacio Angarita
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Eugenia-Lucia Saldarriaga
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Ingris Peláez-Ballestas
Hospital General de Mexico Dr Eduardo Liceaga
Author Profile
Alejandro Silva Espinosa
Grupo de Genética Humana Universidad de La Sabana Chía Colombia
Author Profile
Ignacio Briceño-Balcázar
Grupo de Genética Humana Universidad de La Sabana Chía Colombia
Author Profile
Sofia Arias-Correal
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
José Arias Correal
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Catalina Villota-Erazo
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Viviana Reyes
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Santiago Bernal-Macías
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile
Mario H. Cardiel
Centro de Investigación Clínica de Morelia SC Morelia Mexico
Author Profile
John Londono
Grupo de Espondiloartropatías Rheumatology Department Universidad de La Sabana Chía Colombia
Author Profile

Abstract

Host immune response as well as virulence factors are key in disease susceptibility. There are no known association studies of HLA class I and II alleles with chikungunya (CHIKV) infection in Latin American population. We aim to identify Human Leukocyte Antigen (HLA) alleles present in patients with CHIKV infection when compared to healthy controls, as well as allele association with the clinical spectrum of the disease. A cross-sectional analysis nested in a community cohort was carried out. We included patients 18 years and older with serological confirmation of CHIKV infection. HLA typing of HLA-A, HLA-B and HLA-DRB1 alleles was performed. Two-by-two tables were used to establish associations between allele presence and clinical characteristics. Data from 65 patients with confirmed CHIKV infection were analyzed for HLA typing. CHIKV infection was associated with the presence of HLA-A*68, HLA-B*35, HLA-DRB*01, HLA-DRB1*04 and HLA-DRB1*13 alleles with statistical significance when compared to healthy subjects. A statistically significant relationship was found between the presence of rash in the face or the abdomen and the presence of HLA-DRB1*04. Our study demonstrated that in our cohort, HLA type I as well as type II alleles are associated with CHIKV infection, and specifically an HLA type II allele with dermatological symptoms. Further research is needed to set a path for future investigation on genes outside the HLA system to improve knowledge in the pathophysiology of CHIKV infection and its host-pathogen interaction.
30 Apr 2021Submitted to Transboundary and Emerging Diseases
02 May 2021Submission Checks Completed
02 May 2021Assigned to Editor
12 May 2021Reviewer(s) Assigned
04 Jun 2021Review(s) Completed, Editorial Evaluation Pending
04 Jun 2021Editorial Decision: Revise Minor
21 Jul 20211st Revision Received
21 Jul 2021Assigned to Editor
21 Jul 2021Submission Checks Completed
23 Jul 2021Reviewer(s) Assigned
16 Aug 2021Review(s) Completed, Editorial Evaluation Pending
16 Aug 2021Editorial Decision: Revise Minor
16 Oct 20212nd Revision Received
18 Oct 2021Submission Checks Completed
18 Oct 2021Assigned to Editor
20 Oct 2021Reviewer(s) Assigned
22 Oct 2021Review(s) Completed, Editorial Evaluation Pending
23 Oct 2021Editorial Decision: Accept
Jul 2022Published in Transboundary and Emerging Diseases volume 69 issue 4. 10.1111/tbed.14387